{"success":true,"data":{"pressRelease":{"id":"30671","rtpr_id":"nNFC9VF8pc","ticker":"ATRA","exchange":"NASDAQ","all_tickers":["ATRA"],"title":"ATRA SHAREHOLDER RIGHTS ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026","author":"Newsfile Corp","published_at":"2026-05-11T22:59:16.396Z","article_body":"Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://api.newsfilecorp.com/redirect/ejX2GSMEYB) Encourages Investors Who\nSuffered Losses In Atara To Contact Him Directly To Discuss Their Options\n\nIf you purchased or acquired securities in Atara\n(https://api.newsfilecorp.com/redirect/878rxcOvRX) between May 20, 2024 and\nJanuary 9, 2026 and would like to discuss your legal rights, call Faruqi &\nFaruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.\n1310).\n\n[You may also click here for additional information]\n(https://api.newsfilecorp.com/redirect/y4ngmTbjzD)\n\nNew York, New York--(Newsfile Corp. - May 11, 2026) - Faruqi & Faruqi, LLP\n(https://api.newsfilecorp.com/redirect/1K8kEhRknM), a leading national\nsecurities law firm, is investigating potential claims against Atara\nBiotherapeutics, Inc. (\"Atara\" or the \"Company\") (NASDAQ: ATRA) and reminds\ninvestors of the May 22, 2026 deadline to seek the role of lead plaintiff in a\nfederal securities class action that has been filed against the Company.\n\n(https://images.newsfilecorp.com/files/6455/296974_5b1b6f8ab4e238ba_001full.jpg)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in New\nYork, Pennsylvania, California and Georgia. The firm has recovered hundreds of\nmillions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that: (1) certain manufacturing issues, as well as\ndeficiencies inherent in the ALLELE study, made it unlikely that the FDA would\napprove the tabelecleucel BLA; (2) accordingly, tabelecleucel's regulatory\nprospects were overstated; (3) the aforementioned manufacturing issues also\nsubjected Atara to a heightened risk of regulatory scrutiny, as well as\njeopardized its ongoing clinical trials; (4) all the foregoing was likely to\nhave a significant negative impact on Atara's business and financial\ncondition; and (5) as a result, Defendants' public statements were materially\nfalse and/or misleading at all relevant times.\n\nOn January 12, 2026, Atara issued a press release \"announc[ing] that the U.S.\nFood and Drug Administration (FDA) has issued a Complete Response Letter (CRL)\nfor the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as\nmonotherapy treatment for adult and pediatric patients two years of age and\nolder with Epstein-Barr virus positive post-transplant lymphoproliferative\ndisease (EBV+ PTLD), who have received at least one prior therapy including an\nanti-CD20 containing regimen.\" Atara said that \"[t]he CRL indicates that the\nFDA is unable to approve the EBVALLO™ BLA in its present form\" because,\naccording to the CRL, \"the single arm ALLELE trial, which was previously\nconfirmed by the FDA as adequate to support the BLA filing, is no longer\nconsidered to be adequate to provide evidence of effectiveness for accelerated\napproval. Furthermore, the FDA stated that the trial's interpretability is\nconfounded due to trial study design, conduct, and analysis.\"\n\nOn this news, Atara's stock price fell $7.79 per share, or 56.99%, to close at\n$5.88 per share on January 12, 2026.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding Atara's\nconduct to contact the firm, including whistleblowers, former employees,\nshareholders and others.\n\nTo learn more about the Atara class action, go to www.faruqilaw.com/ATRA or\ncall Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or\n212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/anO24uM5z3), on X\n(https://api.newsfilecorp.com/redirect/2483YT1YLE), or on Facebook\n(https://api.newsfilecorp.com/redirect/Mq2nVtqLbo).\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or\npredict a similar outcome with respect to any future matter. We welcome the\nopportunity to discuss your particular case. All communications will be\ntreated in a confidential manner.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/296974","article_body_html":"","raw_payload":{"data":{"id":"nNFC9VF8pc","title":"ATRA SHAREHOLDER RIGHTS ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026","author":"Newsfile Corp","ticker":"ATRA","created":"2026-05-11T22:59:16.396Z","tickers":["ATRA"],"exchange":"NASDAQ","article_body":"Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://api.newsfilecorp.com/redirect/ejX2GSMEYB) Encourages Investors Who\nSuffered Losses In Atara To Contact Him Directly To Discuss Their Options\n\nIf you purchased or acquired securities in Atara\n(https://api.newsfilecorp.com/redirect/878rxcOvRX) between May 20, 2024 and\nJanuary 9, 2026 and would like to discuss your legal rights, call Faruqi &\nFaruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.\n1310).\n\n[You may also click here for additional information]\n(https://api.newsfilecorp.com/redirect/y4ngmTbjzD)\n\nNew York, New York--(Newsfile Corp. - May 11, 2026) - Faruqi & Faruqi, LLP\n(https://api.newsfilecorp.com/redirect/1K8kEhRknM), a leading national\nsecurities law firm, is investigating potential claims against Atara\nBiotherapeutics, Inc. (\"Atara\" or the \"Company\") (NASDAQ: ATRA) and reminds\ninvestors of the May 22, 2026 deadline to seek the role of lead plaintiff in a\nfederal securities class action that has been filed against the Company.\n\n(https://images.newsfilecorp.com/files/6455/296974_5b1b6f8ab4e238ba_001full.jpg)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in New\nYork, Pennsylvania, California and Georgia. The firm has recovered hundreds of\nmillions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that: (1) certain manufacturing issues, as well as\ndeficiencies inherent in the ALLELE study, made it unlikely that the FDA would\napprove the tabelecleucel BLA; (2) accordingly, tabelecleucel's regulatory\nprospects were overstated; (3) the aforementioned manufacturing issues also\nsubjected Atara to a heightened risk of regulatory scrutiny, as well as\njeopardized its ongoing clinical trials; (4) all the foregoing was likely to\nhave a significant negative impact on Atara's business and financial\ncondition; and (5) as a result, Defendants' public statements were materially\nfalse and/or misleading at all relevant times.\n\nOn January 12, 2026, Atara issued a press release \"announc[ing] that the U.S.\nFood and Drug Administration (FDA) has issued a Complete Response Letter (CRL)\nfor the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as\nmonotherapy treatment for adult and pediatric patients two years of age and\nolder with Epstein-Barr virus positive post-transplant lymphoproliferative\ndisease (EBV+ PTLD), who have received at least one prior therapy including an\nanti-CD20 containing regimen.\" Atara said that \"[t]he CRL indicates that the\nFDA is unable to approve the EBVALLO™ BLA in its present form\" because,\naccording to the CRL, \"the single arm ALLELE trial, which was previously\nconfirmed by the FDA as adequate to support the BLA filing, is no longer\nconsidered to be adequate to provide evidence of effectiveness for accelerated\napproval. Furthermore, the FDA stated that the trial's interpretability is\nconfounded due to trial study design, conduct, and analysis.\"\n\nOn this news, Atara's stock price fell $7.79 per share, or 56.99%, to close at\n$5.88 per share on January 12, 2026.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding Atara's\nconduct to contact the firm, including whistleblowers, former employees,\nshareholders and others.\n\nTo learn more about the Atara class action, go to www.faruqilaw.com/ATRA or\ncall Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or\n212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/anO24uM5z3), on X\n(https://api.newsfilecorp.com/redirect/2483YT1YLE), or on Facebook\n(https://api.newsfilecorp.com/redirect/Mq2nVtqLbo).\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or\npredict a similar outcome with respect to any future matter. We welcome the\nopportunity to discuss your particular case. All communications will be\ntreated in a confidential manner.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/296974"},"type":"article","timestamp":"2026-05-11T22:59:16.442963765Z","server_sent_at_ms":1778540356442},"received_at":"2026-05-11T22:59:16.499Z","source_url":"https://www.newsfilecorp.com/release/296974"},"analysis":{"id":"22727","press_release_id":"30671","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Faruqi & Faruqi issued a shareholder-solicitation notice reminding ATRA investors of a May 22, 2026 deadline to seek lead plaintiff status in a federal securities class action.\n\nThe firm is investigating claims related to alleged false statements regarding manufacturing issues and the FDA's subsequent rejection of the tabelecleucel BLA.\n\nThis is a law-firm marketing notice, not an issuer disclosure or a court action; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"James (Josh) Wilson","role":"Partner at Faruqi & Faruqi, LLP"}],"products":["EBVALLO"],"companies":[{"name":"Faruqi & Faruqi, LLP","relationship":"plaintiff law firm"},{"name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","relationship":"defendant"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Faruqi & Faruqi. No new disclosure from the issuer; routine lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"ATRA"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Faruqi & Faruqi issued a shareholder-solicitation notice reminding ATRA investors of a May 22, 2026 deadline to seek lead plaintiff status in a federal securities class action.\n\nThe firm is investigating claims related to alleged false statements regarding manufacturing issues and the FDA's subsequent rejection of the tabelecleucel BLA.\n\nThis is a law-firm marketing notice, not an issuer disclosure or a court action; treat as low-signal noise.","key_figures":{},"named_entities":{"people":[{"name":"James (Josh) Wilson","role":"Partner at Faruqi & Faruqi, LLP"}],"products":["EBVALLO"],"companies":[{"name":"Faruqi & Faruqi, LLP","relationship":"plaintiff law firm"},{"name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","relationship":"defendant"}],"dollarAmounts":[]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:a76fb3b19e8e8b7b","schema_hash":"sha256:8658c370b800cf3d","created_at":"2026-05-12T02:42:51.191Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":405216,"modelName":"george-droid-qwen-72b"}}